Novel multifunctional oligopeptides

By developing peptide compounds that combine lipids and montelukast, the shortcomings of existing technologies in treating inflammation and promoting healing have been addressed, achieving effective inflammation regulation and wound healing.

CN122122167APending Publication Date: 2026-05-29ENLITISA (SHANGHAI) PHARM CO LTD
10 Cites 0 Cited by

Patent Information

Application Number
CN202480054136.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-22
Filing Date
2024-06-24
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current technology lacks effective drugs to treat inflammation and conditions characterized by inflammation, and traditional anti-inflammatory drugs may interfere with the wound healing process.

Method used

A peptide compound containing a specific structure has been developed for modulating inflammatory responses by combining lipids such as vitamin A, vitamin E, cholesterol, and fatty acids with peptide sequences such as Ala-Lys-Pro-Ser-Tyr-Hyp-Thr-DOPA-Lys, etc., to form a pharmaceutical composition with anti-inflammatory and healing-promoting properties.

Benefits of technology

This compound can effectively regulate the inflammatory response, reduce inflammatory symptoms, and promote wound healing, while avoiding the negative effects of traditional anti-inflammatory drugs on healing.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided is a compound of formula I, Lt-Qa-Db (I) wherein: Qa represents Z or A-Q-B, and Q is a structural fragment of formula II, (II) wherein: the wavy line, R and m have the meanings given in the description, and wherein A and B have the meanings given in the description, but may represent a peptide component of formula (IV) [(W) r-Lys-X1-T-U-X2-Y] n-(W) r-Lys-X1-T-U-X2-Y (IV) wherein n, r, T, W, X1, U, X2 and Y have the meanings given in the description, each L independently represents a lipid as defined in the specification, and D represents one or more optional montelukast moieties, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives, and film-forming materials, and / or in the treatment of conditions characterized by inflammation, including wounds, burns, and mucosal disorders, such as wounds, burns, and mucosal disorders. The mucosal disorders such as anorectal diseases, inflammatory bowel diseases, gynecological diseases, and dental diseases.
Need to check novelty before this filing date? Find Prior Art